dipyridamole has been researched along with Peritoneal Carcinomatosis in 3 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The maximum tolerated dose of etoposide was 175 mg/m2 per day when administered with dipyridamole at a fixed dose of 24 mg/m2 per day." | 2.67 | Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole. ( Braly, PS; Howell, SB; Isonishi, S; Kim, S; Kirmani, S; McClay, EF; Plaxe, SC, 1991) |
| "Chemical peritonitis was the dose-limiting toxicity." | 1.28 | Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole. ( Balis, FM; Cleary, SM; Goel, R; Horton, C; Howell, SB; Kirmani, S; Zimm, S, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Isonishi, S | 1 |
| Kirmani, S | 3 |
| Kim, S | 1 |
| Plaxe, SC | 1 |
| Braly, PS | 1 |
| McClay, EF | 1 |
| Howell, SB | 3 |
| Goel, R | 2 |
| Cleary, SM | 1 |
| Horton, C | 1 |
| Balis, FM | 1 |
| Zimm, S | 1 |
1 trial available for dipyridamole and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Dose-R | 1991 |
2 other studies available for dipyridamole and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Novel approaches to intraperitoneal drug delivery.
Topics: Antineoplastic Agents; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation; Drug Synergi | 1989 |
Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Dipyridamole; Dr | 1989 |